Evidence map›Paper›PMID 33123958›Full record

ArticleJournal of general internal medicine2021

Primary Care Providers' Perceptions About Participating in Low-Risk Prostate Cancer Treatment Decisions.

Archana Radhakrishnan, Lauren P Wallner, Ted A Skolarus, Paul H Abrahamse, Adam S Kollipara, Steven J Katz, Sarah T Hawley

Open access · bronzeAbstract read
In one paragraph

Article in Journal of general internal medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Archana RadhakrishnanDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. arra@med.umich.edu.ORCID 0000-0001-7689-6390
Lauren P WallnerDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Ted A SkolarusDepartment of Urology, University of Michigan, Ann Arbor, MI, USA.
Paul H AbrahamseDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Adam S KolliparaDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Steven J KatzDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Sarah T HawleyDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
University of Michigan · US

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI THEODORE S LAWRENCE · 1988 to 2026
$178.2M
Engaging PCPs to optimize active surveillance of low-risk prostate cancerK08CA245237 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI RADHAKRISHNAN, ARCHANA · 2019 to 2023
$1.2M
NCI NIH HHS K08 CA245237NCI NIH HHS L30 CA242705NCI NIH HHS P30 CA046592
6 · The paper itself

Abstract

backgroundPrimary care provider's (PCP) role in cancer care is expanding and may include supporting patients in their treatment decisions. However, the degree to which PCPs engage in this role for low-risk prostate cancer is unknown.

objectiveCharacterize PCP perceptions regarding their role in low-risk prostate cancer treatment decision-making.

designCross-sectional, national survey. MAIN MEASURES: For men with low-risk prostate cancer, PCP reports of (1) confidence in treatment decision-making (high vs. low); (2) intended participation in key aspects of active surveillance treatment decision-making (more vs. less). KEY

resultsA total of 347 from 741 eligible PCPs responded (adjusted response rate 56%). Half of respondent PCPs (50.3%) reported high confidence about engaging in low-risk prostate cancer treatment decision-making. The odds of PCPs reporting high confidence were greater among those in solo practice (vs working with > 1 PCP) (OR 2.18; 95% CI 1.14-4.17) and with higher volume of prostate cancer patients (> 15 vs. 6-10 in past year) (OR 2.16; 95% CI 1.02-4.61). PCP report of their intended participation in key aspects of active surveillance treatment decision-making varied: discussing worry (62.4%), reviewing benefits (48.5%) and risks (41.8%), and reviewing all treatment options (34.2%). PCPs who reported high confidence had increased odds of more participation in all aspects of active surveillance decision-making: reviewing all treatment options (OR 3.11; 95% CI 1.82-5.32), discussing worry (OR 2.12; 95% CI 1.28-3.51), and reviewing benefits (OR 3.13; 95% CI 1.89-5.16) and risks (OR 3.20; 95% CI 1.91-5.36).

conclusionsThe majority of PCPs were confident about engaging with patients in low-risk prostate cancer treatment decision-making, though their intended participation varied widely across four key aspects of active surveillance care. With active surveillance being considered for other low-risk cancers (such as breast and thyroid), understanding factors influencing PCP involvement will be instrumental to supporting team-based cancer care.

Indexed as

Physicians, Primary CareProstatic NeoplasmsCross-Sectional StudiesHumansMalePerceptionPrimary Health Caredecision-makingprimary careprostatic neoplasmswatchful waiting

Identifiers

PMID33123958
PMCPMC7878590
OpenAlexW3095852570

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.